Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
October 18 2007 - 11:52AM
PR Newswire (US)
DENVER, Oct. 18 /PRNewswire-FirstCall/ -- Global Med
Technologies(R), Inc. (OTC:GLOB) (BULLETIN BOARD: GLOB) , an
international e-Health, medical information technology company,
announced today that its Wyndgate Technologies(R) division
("Wyndgate") has submitted its ElDorado Donor(TM) software for a
510(k) clearance by the U.S. Food and Drug Administration (FDA).
ElDorado Donor is currently not for sale in the U.S., pending
510(k) clearance by the FDA. ElDorado Donor is intended as a
comprehensive blood management software application designed to
provide for the information system needs of a blood bank and donor
centers. The software is designed to manage, automate, and control
activities associated with donors, donor collections, testing,
manufacturing, inventory, and distribution. ElDorado Donor was
developed with scalability in mind and is designed to manage the
system needs of diverse facilities, from small hospital blood banks
to community blood centers, to regional and national centers, both
domestically and internationally. Utilizing an integrated modular
configuration, ElDorado Donor is intended to offer functionality
with flexibility to tailor features within the system to a
facility's specific needs and to support process control from
collection to distribution. The software is designed for
ease-of-use and includes drop down lists and easy access find
forms. Wyndgate's At-a-Glance(TM) bars are to provide a visual
indication of the presence of relevant information that can be
viewed and provide quick and easy access to the information.
ElDorado Donor is designed to support the upcoming industry
standard for labeling (ISBT128), as well as the ABC Codabar blood
product labeling standard. ElDorado Donor is to include safety
checks for blood components, blood products, and other related
supply items. These safety checks are to be performed throughout
the system as part of the normal processing of donors, blood
components, and other blood products. ElDorado Donor is to provide
extensive manufacturing controls that can be tailored for a
specific site depending on its processes. The blood management
software has been designed with guidance from Wyndgate's technology
workgroup, comprised of leading industry representatives from
around the world. Throughout the ElDorado Donor development
process, the work group's contributions assisted the Company in
delivering a feature-rich and user-friendly solution. Miklos Csore,
Vice President of Research and Development, commented, "Global Med
Technologies and Wyndgate Technologies are delighted that ElDorado
Donor has been submitted for FDA 510(k) clearance. Wyndgate's
management and staff have strived to provide an innovative quality
healthcare solution, which will assist our customers in meeting
their business and regulatory needs. We wish to thank our
technology work group, who has been invaluable throughout this
process." Mr. Csore continued, "We look forward to the response
from FDA regarding clearance for ElDorado Donor." About Global Med
Technologies, Inc. Global Med Technologies(R), Inc. is an
international e-Health medical information technology company
providing information management software products and services to
the healthcare industry. Its Wyndgate Technologies(R) division is a
leading supplier of information management systems to U.S. and
international blood centers and hospital transfusion centers. Each
year, Wyndgate's products and services manage more than eight
million blood components, representing over 27% of the U.S. blood
supply. Wyndgate's products are also being used in Canada and
sub-Saharan Africa, and are being implemented in the Caribbean.
Together, the Donor Doc(TM) interactive donor health history
questionnaire, SafeTrace(R) donor management system, and the
SafeTrace Tx(R) advanced transfusion management system, recently
patented, provide Vein-to-Vein(R) tracking from donor collection to
patient transfusion. For more information about Global Med's
products and services, please call 800-WYNDGATE or visit
http://www.globalmedtech.com/, http://www.peoplemed.com/ and
http://www.wyndgate.com/. This news release may include statements
that constitute forward-looking statements, usually containing the
words "believe," "estimate," "project," "expects" or similar
expressions. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this news release. DATASOURCE: Global Med Technologies, Inc.
CONTACT: Company Contact, Michael I. Ruxin, M.D. of Global Med
Technologies, Inc., +1-303-238-2000, ; or Investors, Paul Holm of
H.L. Lanzet, Inc., +1-212-888-4570, , for Global Med Technologies,
Inc. Web site: http://www.globalmedtech.com/
Copyright